Compare WETH & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | WETH | NRXS |
|---|---|---|
| Founded | 1992 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.1M | 25.8M |
| IPO Year | N/A | 2023 |
| Metric | WETH | NRXS |
|---|---|---|
| Price | $1.68 | $2.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 90.6K | 51.1K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.55 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $43,519,385.00 | $3,362,320.00 |
| Revenue This Year | N/A | $31.05 |
| Revenue Next Year | N/A | $137.61 |
| P/E Ratio | $2.82 | ★ N/A |
| Revenue Growth | 6.08 | ★ 36.89 |
| 52 Week Low | $0.76 | $1.33 |
| 52 Week High | $3.68 | $6.20 |
| Indicator | WETH | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 37.09 | 47.00 |
| Support Level | $1.75 | $2.50 |
| Resistance Level | $2.04 | $2.78 |
| Average True Range (ATR) | 0.17 | 0.15 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 4.26 | 39.41 |
Wetouch Technology Inc is a touch panel supplier focused on R&D, production, and sales of touch screen products. It offers touchscreens for a variety of applications, including GPS/car entertainment panels for the automotive industry, industrial human-machine interface, financial and banking terminals, point of sale, lottery and gaming machines, smart home, robots, and charging stations. The company sells touchscreen products both domestically in China and internationally. The company generates the majority of its revenue from the PRC, followed by the Republic of China and Korea.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).